%20(1).jpg)
From relapse to remission: What an indigenous CAR-T therapy signals for India’s cancer market
When Dr Arora was diagnosed with non-Hodgkin’s lymphoma in 2022, she crossed overnight from a practising doctor to a patient. Her recovery with ImmunoACT’s indigenous CAR-T therapy now sits at the intersection of medicine and markets, drawing interest in whether an Indian company can sustainably manufacture, price, and scale one of the world’s most complex cancer treatments. Two years after its commercial launch, ImmunoACT’s NexCAR19 has been administered to more than 600 patients with relapsed or refractory acute lymphoblastic leukaemia (r/r ALL) and non-Hodgkin’s lymphoma (NHL). The therapy is priced at a fraction of the ₹4–10 crore range typically associated with imported CAR-T products, a differential that directly shapes access in India’s largely self-pay oncology market. CAR-T, in simple terms, is a personalised treatment in which a patient’s own immune T- cells are genetically modified to recognise and kill cancer cells, then infused back into the body. Following Dr Arora’s diagnosis in 2022, she was first treated at Rajiv Gandhi Cancer Institute. Standard therapies initially worked, but she later relapsed. That clinical setback led her to Tata Memorial Hospital, one of the apex centres in India equipped to deliver cell and gene therapies. At Tata Memorial, Dr Arora received NexCAR19 under a specialist team. Over the following months, she recovered and eventually returned to medical practice. Individual outcomes vary, but such recoveries feed into a larger debate on whether CAR-T can move beyond “last-resort” use if durability holds up over time. ImmunoACT’s NexCAR19 holds a US patent as the world’s first humanised CAR-T therapy, a design choice that the company says may reduce severe side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Durability of response is also emerging as a key metric. Patients like Dr Arora, who have remained in complete remission for more than two years after infusion, suggest the therapy may deliver sustained benefit. In CAR-T globally, long-term remission is what ultimately justifies both the clinical risk and the upfront cost. “Relapse felt like the ground slipping beneath my feet. But receiving timely CAR-T treatment gave me another chance—not just to live, but to return to the life I love. I stand here as proof that relapse is not the end; it can be a new beginning. Post-CAR-T treatment, I have been cancer-free for more than two and a half years and have resumed my clinical practice and family life,” Dr Arora shared with our team. A treating clinician at Tata Memorial Hospital added: “Stories like Dr Arora’s reflect how far cell and gene therapy has progressed. At Tata Memorial Hospital, we have witnessed many similar successes with indigenous CAR-T therapy, where patients have remained disease-free for extended periods. This marks a real turning point in the treatment of difficult blood cancers.” From an economics and manufacturing standpoint, the affordability narrative rests on domestic production. ImmunoACT’s NexCAR19 is fully manufactured in India, avoiding the cost and time associated with shipping patient cells overseas or importing raw materials or the finished product. The company cites what it describes as best-in-the- world control over manufacturing success rates, logistics, and a turnaround time of around 17–20 days. Policy and payor support will be critical for wider uptake of CAR-T therapies in India, where most patients continue to fund treatment out of pocket, with limited private insurance coverage and uneven reimbursement from state schemes. To ease this access barrier, ImmunoACT has launched ‘The Hope Initiative’ in partnership with Mango Sciences, offering two patient-support programmes—Bridge Financing and Value-Based Pricing. The Bridge Financing programme provides a ₹10 lakh loan at 0% interest EMIs to address cash-flow constraints during treatment, while the Value-Based Pricing programme offers a rebate on the overall cost if a patient relapses within 12 months. The company recently announced the onboarding of its first patient under ‘The Hope Initiative’ on World Cancer Day via its social media channels. Dr Arora’s journey is more than a personal victory—it is a glimpse into the future of cancer care in India, where innovation, accessibility, and human resilience come together to offer patients something priceless: a real second chance at life. For the industry, regulators, and investors, what to watch next are longer-term efficacy results, transparent disclosures on safety data and patient profiles, and whether insurers or government payors move to formally reimburse CAR-T therapies in India.
When Dr Arora was diagnosed with non-Hodgkin’s lymphoma in 2022, she crossed overnight from a practising doctor to a patient. Her recovery with ImmunoACT’s indigenous CAR-T therapy now sits at the intersection of medicine and markets, drawing interest in whether an Indian company can sustainably manufacture, price, and scale one of the world’s most complex cancer treatments.
Two years after its commercial launch, ImmunoACT’s NexCAR19 has been administered to more than 600 patients with relapsed or refractory acute lymphoblastic leukaemia (r/r ALL) and non-Hodgkin’s lymphoma (NHL). The therapy is priced at a fraction of the ₹4–10 crore range typically associated with imported CAR-T products, a differential that directly shapes access in India’s largely self-pay oncology market.
CAR-T, in simple terms, is a personalised treatment in which a patient’s own immune T- cells are genetically modified to recognise and kill cancer cells, then infused back into the body. Following Dr Arora’s diagnosis in 2022, she was first treated at Rajiv Gandhi Cancer Institute. Standard therapies initially worked, but she later relapsed.
That clinical setback led her to Tata Memorial Hospital, one of the apex centres in India equipped to deliver cell and gene therapies. At Tata Memorial, Dr Arora received NexCAR19 under a specialist team. Over the following months, she recovered and eventually returned to medical practice. Individual outcomes vary, but such recoveries feed into a larger debate on whether CAR-T can move beyond “last-resort” use if durability holds up over time.
ImmunoACT’s NexCAR19 holds a US patent as the world’s first humanised CAR-T therapy, a design choice that the company says may reduce severe side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Durability of response is also emerging as a key metric. Patients like Dr Arora, who have remained in complete remission for more than two years after infusion, suggest the therapy may deliver sustained benefit. In CAR-T globally, long-term remission is what ultimately justifies both the clinical risk and the upfront cost.
“Relapse felt like the ground slipping beneath my feet. But receiving timely CAR-T treatment gave me another chance—not just to live, but to return to the life I love. I stand here as proof that relapse is not the end; it can be a new beginning. Post-CAR-T treatment, I have been cancer-free for more than two and a half years and have resumed my clinical practice and family life,” Dr Arora shared with our team.
A treating clinician at Tata Memorial Hospital added: “Stories like Dr Arora’s reflect how far cell and gene therapy has progressed. At Tata Memorial Hospital, we have witnessed many similar successes with indigenous CAR-T therapy, where patients have remained disease-free for extended periods. This marks a real turning point in the treatment of difficult blood cancers.”
From an economics and manufacturing standpoint, the affordability narrative rests on domestic production. ImmunoACT’s NexCAR19 is fully manufactured in India, avoiding the cost and time associated with shipping patient cells overseas or importing raw materials or the finished product. The company cites what it describes as best-in-the- world control over manufacturing success rates, logistics, and a turnaround time of around 17–20 days.
Policy and payor support will be critical for wider uptake of CAR-T therapies in India, where most patients continue to fund treatment out of pocket, with limited private insurance coverage and uneven reimbursement from state schemes. To ease this access barrier, ImmunoACT has launched ‘The Hope Initiative’ in partnership with Mango Sciences, offering two patient-support programmes—Bridge Financing and Value-Based Pricing. The Bridge Financing programme provides a ₹10 lakh loan at 0% interest EMIs to address cash-flow constraints during treatment, while the Value-Based Pricing programme offers a rebate on the overall cost if a patient relapses within 12 months. The company recently announced the onboarding of its first patient under ‘The Hope Initiative’ on World Cancer Day via its social media channels.
Dr Arora’s journey is more than a personal victory—it is a glimpse into the future of cancer care in India, where innovation, accessibility, and human resilience come together to offer patients something priceless: a real second chance at life. For the industry, regulators, and investors, what to watch next are longer-term efficacy results, transparent disclosures on safety data and patient profiles, and whether insurers or government payors move to formally reimburse CAR-T therapies in India.
